Ozempic patent cliff: what happens when generic semaglutide arrives

Ozempic’s core patents are expiring. What that actually means for access — and for pricing — is more complicated than the headlines suggest.

TL;DR

• Semaglutide’s primary patent expires around 2026, but Novo Nordisk holds a web of secondary patents that could extend exclusivity to 2031.
• Biosimilars — not traditional generics — are what’s coming, and FDA approval for biologics takes longer than for pills.
• Compounded semaglutide is legally distinct from a generic and operates under a different regulatory framework.

What it is

A “patent cliff” happens when a drug’s intellectual property protection expires and lower-cost competitors are legally allowed to enter the market. For semaglutide — the active ingredient in Ozempic and Wegovy — the primary composition-of-matter patent is set to expire in the late 2020s. That’s the one that protects the molecule itself. But drug companies routinely file additional patents on delivery devices, formulations, and dosing methods, and Novo Nordisk has done exactly that. These secondary patents could keep generic manufacturers out of the market until the early 2030s.

How it works

Semaglutide is a GLP-1 receptor agonist (in plain English: a molecule that mimics the gut hormone GLP-1, which signals fullness and regulates blood sugar). Because semaglutide is a large, complex peptide — not a simple chemical compound — it’s classified as a biologic. That matters for competition. Traditional small-molecule drugs (like metformin) can be copied as exact chemical generics. Biologics can only be copied as biosimilars (highly similar versions that require separate FDA approval demonstrating equivalence in safety and effect). The biosimilar pathway is slower and more expensive than the generic pathway.

Who asks about it

People currently taking Ozempic or Wegovy — or those priced out of access — want to know when a cheaper version might arrive. The question also comes up from people comparing compounded semaglutide to what a future “generic” might look like.

What the research says

As of 2026, multiple manufacturers have filed applications to develop semaglutide biosimilars. The FDA has a dedicated biosimilar review track, and approval timelines for comparable drugs have run two to four years from filing. Litigation between Novo Nordisk and compounding pharmacies — including Novo Nordisk v. Hims & Hers (Feb 2026) — is reshaping who can legally produce semaglutide in the interim period.

What to know before considering it

Compounded semaglutide prepared by a state-licensed 503A pharmacy is not a generic and is not the same as a future biosimilar. It is made from the FDA-approved active pharmaceutical ingredient, not copied from the branded drug. Any access to compounded or biosimilar semaglutide requires a licensed clinician’s evaluation and prescription.

The Halftime POV

The patent cliff is real, but “generic Ozempic next year” is not. The more near-term access question is how the compounded pharmacy market evolves alongside biosimilar development. For most people, physician-supervised access through a licensed telehealth provider is the clearest path right now.

Related reading:

• What changed when compounded semaglutide became legal
• The Novo Nordisk vs. compounders litigation explained
• How the 503A compounding framework works

FAQ

Q: When does Ozempic go generic? A: Semaglutide’s core composition-of-matter patent expires around 2026, but Novo Nordisk holds additional formulation and method-of-use patents that could extend market exclusivity to 2031 or beyond. Biosimilar manufacturers are actively challenging these.

Q: Is a biosimilar the same as a generic? A: Not quite. A biosimilar is demonstrated to be highly similar to the original biologic, but GLP-1 drugs like semaglutide are complex molecules — the FDA approval process for biosimilars is more involved than for small-molecule generics.

Q: How is compounded semaglutide different from a generic? A: Compounded semaglutide is prepared by state-licensed 503A pharmacies from the FDA-approved active pharmaceutical ingredient, not from the branded product. It is not a generic and is not itself FDA-approved.

Disclaimer

This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb 2026). Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• FDA Biosimilar Development
• Semaglutide — PubChem Compound Summary
• Novo Nordisk 2025 Annual Report — Patent Disclosure